ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.898,80
1,23%
S&P 500
5.352,96
-0,02%
US Dollar vs BRL
5,2591
0,01%
Bitcoin
71.213,50
0,64%
Brent Oil
79,785
-0,12%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Talaris Therapeutics Inc (TALS)

  7. Talaris Therapeutics Inc (TALS) Notícias

TALS

Talaris Therapeutics (TALS)

Talaris Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TALS
DataHoraFonteTítuloCódigoCompanhia
19/04/202417:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:TALSTalaris Therapeutics Inc
19/04/202417:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TALSTalaris Therapeutics Inc
19/04/202417:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TALSTalaris Therapeutics Inc
19/03/202418:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TALSTalaris Therapeutics Inc
19/03/202418:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TALSTalaris Therapeutics Inc
19/03/202408:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TALSTalaris Therapeutics Inc
20/11/202320:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TALSTalaris Therapeutics Inc
06/11/202318:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TALSTalaris Therapeutics Inc
30/10/202317:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
17/10/202318:47GlobeNewswire Inc.Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioNASDAQ:TALSTalaris Therapeutics Inc
10/10/202317:32Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:TALSTalaris Therapeutics Inc
10/10/202317:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
06/10/202321:01Dow Jones NewsStocks to Watch: Shift Technologies, Talaris Therapeutics, Lockheed MartinNASDAQ:TALSTalaris Therapeutics Inc
06/10/202318:09GlobeNewswire Inc.Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioNASDAQ:TALSTalaris Therapeutics Inc
04/10/202309:30GlobeNewswire Inc.New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics Inc
15/09/202307:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TALSTalaris Therapeutics Inc
15/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TALSTalaris Therapeutics Inc
13/09/202317:28Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:TALSTalaris Therapeutics Inc
14/08/202308:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TALSTalaris Therapeutics Inc
22/06/202310:12Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:TALSTalaris Therapeutics Inc
22/06/202308:30GlobeNewswire Inc.Talaris Therapeutics and Tourmaline Bio Announce Merger AgreementNASDAQ:TALSTalaris Therapeutics Inc
14/06/202320:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TALSTalaris Therapeutics Inc
30/05/202317:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TALSTalaris Therapeutics Inc
26/05/202308:00GlobeNewswire Inc.Talaris Therapeutics Announces Leadership TransitionNASDAQ:TALSTalaris Therapeutics Inc
15/05/202317:34Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TALSTalaris Therapeutics Inc
28/04/202317:42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TALSTalaris Therapeutics Inc
28/04/202317:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TALSTalaris Therapeutics Inc
28/04/202317:09Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TALSTalaris Therapeutics Inc
27/04/202315:20Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:TALSTalaris Therapeutics Inc
07/04/202317:20Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:TALSTalaris Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TALS

Seu Histórico Recente

TSXV
WITT.P
Wittering Capital
EU
BNPJC
BNP Paribas SA 0.375% un...
EU
FR001400O4Y9
BPCE Bpce Frn 23feb2025
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados